
The FUN of Schizophrenia
I start on this medication tomorrow.. finally after 3 years I get to change meds.

Risperidone
From Wikipedia, the free encyclopedia
Risperidone (pronounced Ris-PER-ǐ-dōn and sold under the trade name Risperdal in the United States, Canada, the United Kingdom, Portugal and several other countries, Risperdal or Ridal in New Zealand, Rispolept in Eastern Europe, and Belivon, or Rispen elsewhere) is an atypical antipsychotic medication developed by Janssen Pharmaceutica.
Uses
Risperidone was approved by the United States Food and Drug Administration (FDA) in 1993[1] for the treatment of schizophrenia. On Wednesday, August 22, 2007,
Risperdal was approved as the only drug agent available for treatment
of schizophrenia in children ages 13–18; it was also approved that same
day for treatment of bipolar disorder in youths ages 10–18, joining lithium. Risperidone contains the functional groups of benzisoxazole and piperidine
as part of its molecular structure. In 2003 the FDA approved
risperidone for the short-term treatment of the mixed and manic states
associated with bipolar disorder.
In 2006 the FDA approved risperidone for the treatment of irritability
in children and adolescents with autism. Like other atypical
antipsychotics, it has also been used off-label
for the treatment of anxiety disorders, such as Obsessive-Compulsive
disorder; severe, treatment-resistant depression with or without
psychotic features; Tourette's disorder; disruptive behavior disorders
in children; and eating disorders, among others.[2]
A multi-year UK study by the Alzheimer's Research Trust suggested that this and other neuroleptic anti-psychotic drugs commonly given to Alzheimer's patients with mild behavioural problems often make their condition worse. [3] The study concluded that
| “ |
For most patients with AD,
withdrawal of neuroleptics had no overall detrimental effect on
functional and cognitive status and by some measures improved
functional and cognitive status. Neuroleptics may have some value in
the maintenance treatment of more severe neuropsychiatric symptoms, but
this possibility must be weighed against the unwanted effects of
therapy. The current study helps to inform a clinical management
strategy for current practice, but the considerable risks of
maintenance therapy highlight the urgency of further work to find,
develop, and implement safer and more effective treatment approaches
for neuropsychiatric symptoms in people with AD. |
Risperidone is a strong dopamine blocker (antagonist); i.e., it inhibits functioning of postsynaptic dopamine receptors.
It reaches peak plasma
levels quickly regardless of whether it is administered as a liquid or
pill. The strong dopamine-blocking reaction is known to make some
people feel nauseated if they do things that normally trigger the dopamine response, such as eat a pleasing meal or experience orgasm[original research?][citation needed]. Risperidone is metabolised
fairly quickly, so this potential for nausea subsides usually in two to
three hours. However the active metabolite, 9-hydroxy-risperidone,
which has similar pharmacodynamics to risperidone, lingers in the body
for much longer.
An intramuscular preparation, marketed as Risperdal Consta, can be
given once every two weeks. It is slowly released from the injection
site. It can be useful in patients who have difficulty taking oral
medication for any reason. Some people prefer a once-every-two-weeks
injection to daily pills. It also helps the physician ensure
compliance. Doses range from 25 to 50 mg given as an intramuscular
injection once every two weeks.
{FROM WIKIPEDIA}
Chatboard (0)